

**Procter & Gamble – I.P. Division****IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND  
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****RECEIVED  
CENTRAL FAX CENTER****JUN 02 2004**

**TO: United States Patent and Trademark Office  
Group Art Unit 1614  
Fax No. 703-872-9306**

**OFFICIAL**

*I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on June 2, 2004, to the above-identified facsimile number.*

Laura L. Fricke (Signature)

**FROM: Laura L. Fricke (Typed or printed name of person signing Certificate)**

**Fax No. (513) 626-1355**

**Phone No. (513) 626-2721**

Listed below are the item(s) being submitted with this Certificate of Transmission:\*\*

- 1) Information Disclosure Statement, and one copy for authorization to charge fee to Deposit Account;
- 2) PTO/SB08 (2 pages);

Number of Pages Including this Page: 9

Inventor(s): Bissett

S.N.: ~~10/789,267~~

Filed: 02/17/2004 *OK*

Conf. No.: 2224

Case: 9176R

Comments:

**\*\*Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.**

P&amp;G Case 9176R

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
D. L. Bissett : Confirmation No. 2224  
Serial No. 10/780,267 : Group Art Unit 1614  
Filed February 17, 2004 : Examiner

For Regulation of Mammalian Keratinous tissue Using Hexamidine Compositions

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3)** - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4)** - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment** - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).**

This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☐ (1) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☒ (2) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 9176, U.S. Patent Application Serial No. 10/379,252, filed March 4, 2003. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (3) Copies of all said documents, except Cite Numbers \_\_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (5) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By Laura L. Frieko  
Laura L. Frieko  
Attorney for Applicant  
Registration No. 52,920  
(513) 626-2721

June 2, 2004

Customer No. 27752

P&amp;G Case 9176R

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
D. L. Bissett : Confirmation No. 2224  
Serial No. 10/780,267 : Group Art Unit 1614  
Filed February 17, 2004 : Examiner

RECEIVED  
CENTRAL FAX CENTER  
JUN 02 2004

For Regulation of Mammalian Keratinous tissue Using Hexamidine Compositions

INFORMATION DISCLOSURE STATEMENT**OFFICIAL**

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).  
This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☐ (1) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☒ (2) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 9176, U.S. Patent Application Serial No. 10/379,252, filed March 4, 2003. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (3) Copies of all said documents, except Cite Numbers \_\_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (5) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By Laura L. Frieko  
Laura L. Frieko  
Attorney for Applicant  
Registration No. 52,920  
(513) 626-2721

June 2, 2004

Customer No. 27752

Please type a plus sign (+) inside this box → (+)

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## COMPLETE IF KNOWN

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

Application Number	10/780,267
Confirmation Number	2224
Filing Date	02/17/2004
First Named Inventor	Donald Lynn Bissett
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	9176R

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup>	(if known)			
	01	US 4505924 A		05/19/1985	Taylor et al.	
	02	US 4559054 A		12/17/1985	Bruck	
	03	US 5093109 A		03/03/1992	Mausner	
	04	US 5100674 A		03/31/1992	Ser et al.	
	05	US 5614178 A		03/25/1997	Bloom et al.	
	06	US 5679374 A		10/21/1997	Franchon et al.	
	07	US 5716800 A		02/10/1998	Meybeck et al.	
	08	US 6153209 A		11/28/2000	Vega et al.	
	09	US 6207598 B1		03/27/2001	Rourke et al.	
	10	US 6238682 B1		05/29/2001	Klofta et al.	
	11	US 6344218 B1		02/05/2002	Dodd et al.	
	12	US 2002/028222 A1		03/07/2002	Alfriat et al.	
	13	US 2002/034480 A1		03/21/2002	Grimm et al.	
	14	US 2002/041854 A1		04/11/2002	Hadasch et al.	
	15	US 2002/058010 A1		05/16/2002	Picard-Lesbouvryes et al.	
	16	US 6451850 B1		09/17/2002	Soloviev et al.	
	17	US 2002/164294 A1		11/07/2002	Christophides-Lordi et al.	
	18	US 2002/165508 A1		11/07/2002	Klofta et al.	
	19	US 2002/182158 A1		12/05/2002	Christophides-Lordi et al.	
	20	US 2002/192169 A1		12/19/2002	Chevalier et al.	
	21	US 2002/192245 A1		12/19/2002	Jensen et al.	
	22	US 2002/192246 A1		12/19/2002	Jensen et al.	
	23	US 2003/035824 A1		02/20/2003	Isele et al.	
	24	US 2003/077307 A1		04/24/2003	Guirmand et al.	
	25	US 2003/078172 A1		04/24/2003	Guirmand et al.	
	26	US 2003/082219 A1		05/01/2003	Warren et al.	
	27	US 6570054 B1		05/27/2003	Gatto et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	†*
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	28	EP	0 682 868 A1		11/22/1995	CNEVA		X
	29	EP	0 925 783 A1		06/30/1999	SPIRIG AG Pharm.		Abstract
	30	EP	1 103,246 A1		05/30/2001	Cognis Corporation		
	31	EP	1 310 235 A2		05/14/2003	Biersdorf AG		Abstract
	32	FR	2614788 B1		11/10/1988	Richard Marcel		Abstract
	33	FR	2675341 A		10/23/1992	CNEVA		X
	34	FR	2800262 A		05/04/2001	Castro L		Abstract
	35	FR	2813019 A		02/22/2002	L'Oreal SA		Abstract
	36	GB	2216793 B		10/18/1989	Levy		
	37	WO	91/17237		11/14/1991	Procter & Gamble Co.		
	38	WO	91/17237 A1		11/14/1991	Procter & Gamble	= CN1055109A	
	39	WO	95/18600 A1		07/13/1995	Pierre Fabre Dermo-Cosm.		Abstract



Please type a plus sign (+) inside this box → (+)

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

SHEET 2 of 2

**COMPLETE IF KNOWN**

Application Number	10/780,267
Confirmation Number	
Filing Date	02/17/2004
First Named Inventor	Donald Lynn Bissett
Group Art Unit	
Examiner Name	
Attorney Docket Number	9176R

**FOREIGN PATENT DOCUMENTS - Continued**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Country Code <sup>2</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	40	WO	99/45973 A1		09/16/1999	Procter & Gamble		
	41	WO	99/45974 A1		09/16/1999	Procter & Gamble		
	42	WO	2000/074843 A1		12/14/2000	Procter & Gamble		
	43	WO	2001/017585 A2		03/15/2001	Procter & Gamble		
	44	WO	2001/043717 A1		06/21/2001	Procter & Gamble		
	45	WO	2002/047652 A1		06/20/2002	L'Oreal		Abstract
	46	WO	2003/030858 A1		04/17/2003	Biersdorf AG		
	47	WO	2003/030859 A2		04/17/2003	Biersdorf AG		

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T <sup>6</sup>
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.